Tagged with UCB

Global UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus. Speaking at the recent FT Global Pharma and Biotech Summit, CEO Jean-Christophe Tellier discussed the Belgian midcap’s digital undertakings and…

Italy Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in the country’s National Recovery and Resilience Plan and a priority within its healthcare modernisation plans.   Novel solutions came out…

Italy UCB Italy’s Managing Director, Federico Chinni offeres his insights into UCB’s positioning and its new product launches, the first for the company in ten years. He also weighs in on Italy’s national Recovery and Resilience Plan and explains how the company was ready for digitalisation even before the pandemic.  Our…

Spain UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the importance of R&D – UCB spent around 28 percent of its revenues on R&D in 2021. In addition, Ricós analyses Spain’s slow access to innovation and the pros…

Switzerland Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up manufacturing capacity and scope, and why greater levels of both internal and external collaboration are crucial for the pharma industry…

Mexico UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region carries for the firm.   The upcoming three years are crucial and UCB Mexico wants to play a role elevating…

Belgium After reaching revenues of EUR 2.323 billion in the first six months of 2019, UCB announced on December 18 that it will build an innovative multi-product biological manufacturing facility on their site in Braine l’Alleud, Wallonia, Belgium.   Headquartered in Brussels, UCB is a global biopharmaceutical company developing innovative medicines…

Belgium Jean-Christophe Tellier became UCB’s CEO on January 1, 2015 only a few years joining the company in 2011. Before taking on the role Tellier held positions as executive VP of European Operations and later successfully led UCB’s BioBrands and Solutions division as executive VP as well.   Tellier was trained…

Spain Jesús Sobrino, area head of UCB Iberia, and global leader for UCB’s Patients Experience Program, discusses the significance of the affiliate, which makes up 15 percent of UCB’s European sales, and their strategy to strengthen and grow their portfolio. Furthermore, he highlights the challenges of market access in the Spanish…

France Newly-appointed general manager of UCB France, Catherine Rives, discusses what drew her back to the company after time away, market access issues in France and the future of personalized medicine.   My mission is very clearly to raise the profile of the French affiliate within the UCB Group and simultaneously…

Austria Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative products. Globally, UCB registered nine percent growth for the first nine months of 2017. How would you describe the contribution…

Switzerland Nicolas Hug reveals how UCB´s new facility in Bulle, Switzerland, is one of the largest microbial derived pharmaceuticals plants in Europe; how the key challenge for manufacturers today is to guarantee supplies by building a robust network; and why manufacturing is where dreams become reality, taking the results from a…